• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Combination of Nanovectorized siRNA Directed against Survivin with Doxorubicin for Efficient Anti-Cancer Activity in HER2+ Breast Cancer Cells
In conclusion, a combination of anti-Survivin siRNA and DOX would be a good alternative in HER2+ breast cancer therapy.PMID:36432729 | DOI:10.3390/pharmaceutics14112537
Source: Cancer Control - November 26, 2022 Category: Cancer & Oncology Authors: Sahar Eljack Emilie Allard-Vannier Yoann Misericordia Katel Herv é-Aubert Nicolas Aubrey Igor Chourpa Areeg Faggad Stephanie David Source Type: research

Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance
AbstractCancer has presented to be the most challenging disease, contributing to one in six mortalities worldwide. The current treatment regimen involves multiple rounds of chemotherapy administration, alone or in combination. The treatment has adverse effects including cardiomyopathy, hepatotoxicity, and nephrotoxicity. In addition, the development of resistance to chemo has been attributed to cancer relapse and low patient overall survivability. Multiple drug resistance development may be through numerous factors such as up-regulation of drug transporters, drug inactivation, alteration of drug targets and drug degradatio...
Source: Apoptosis - June 18, 2022 Category: Molecular Biology Source Type: research

Silencing of HIF-1 α/CD73 axis by siRNA-loaded TAT-chitosan-spion nanoparticles robustly blocks cancer cell progression.
This study suggested that TAT-TMC-TC-SPIONs can be potential nanocarrier for gene transfection in cancer therapy. Moreover, the co-silencing of CD73 and HIF-1α can be assumed as a novel anti-cancer treatment strategy with high tumor suppression potential. PMID: 32574672 [PubMed - as supplied by publisher]
Source: European Journal of Pharmacology - June 19, 2020 Category: Drugs & Pharmacology Authors: Hajizadeh F, Ardebili SM, Moornani MB, Masjedi A, Atyabi F, Kiani M, Namdar A, Karpisheh V, Izadi S, Baradaran B, Azizi G, Ghalamfarsa G, Sabz G, Yousefi M, Jadidi-Niaragh F Tags: Eur J Pharmacol Source Type: research

PGC1 β Regulates Breast Tumor Growth and Metastasis by SREBP1-Mediated HKDC1 Expression
Conclusions: PGC1β regulates breast cancer tumor growth and metastasis by SREBP1-mediated HKDC1 expression. This provides a novel therapeutic strategy through targeting the PGC1β/HKDC1 signaling pathway for breast cancer treatment. Introduction Breast cancer is a very common cancer with significant premature mortality in women. Around 12% of women in USA will have chance to be diagnosed with breast cancer during their lifetimes (1, 2). The development of breast cancer is regulated by many factors, and even as average survival rates have increased significantly as a result of many advanced treatments...
Source: Frontiers in Oncology - April 16, 2019 Category: Cancer & Oncology Source Type: research

Magnetically responsive hybrid nanoparticles for in vitro siRNA delivery to breast cancer cells
Publication date: June 2019Source: Materials Science and Engineering: C, Volume 99Author(s): Milene Dalmina, Frederico Pittella, Jelver Alexander Sierra, Gabriela Regina Rosa Souza, Adny Henrique Silva, André Avelino Pasa, Tânia Beatriz Creczynski-PasaAbstractShort interfering RNA (siRNA) showed to be a viable alternative to a better prognosis in cancer therapy. Nevertheless, the successful application of this strategy still depends on the development of nanocarriers for the safe delivery of siRNA into the diseased tissue, which mostly occurs by passive accumulation. When an external magnetic field is applied, magnetic n...
Source: Materials Science and Engineering: C - February 23, 2019 Category: Materials Science Source Type: research

Engineering Multifunctional RNAi Nanomedicine to Concurrently Target Cancer Hallmarks for Combinatorial Therapy.
Abstract Cancer hallmarks have been providing a logical framework for understanding the complexity and heterogeneity of tumor biology, leading to the discovery of various promising targets for cancer therapy. Herein, we report a novel amorphous iron oxide nanoparticle (NP)-based RNAi strategy to co-target two cancer hallmarks. The NP technology can modulate the glycolysis pathway by silencing MCT4 to induce tumor cell acidosis, and concurrently exacerbate oxidative stress in tumor cells via the Fenton-like reaction. Our platform shows following appealing features for systemic siRNA delivery: (i) siRNA is encapsula...
Source: Angewandte Chemie - December 24, 2017 Category: Chemistry Authors: Liu Y, Ji X, Tong W, Askhatova D, Yang T, Cheng H, Wang Y, Shi J Tags: Angew Chem Int Ed Engl Source Type: research